Colorectal Cancer Clinical Trial
Official title:
PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the
Western world, with 500000 deaths per year worldwide. Colonoscopy is accepted as a primary
CRC screening tool in many countries. As a preventative procedure, its main purpose is to
enable the early diagnosis of CRC at a curable stage and to identify and remove
pre-malignant adenomas. Cecal intubation is associated with an increased detection rate of
advanced neoplasia, as 33-50% of advanced neoplasia is located in the proximal colon.
Complete colonic evaluation is therefore a well-recognized measure of colonoscopy quality
control. Cecal intubation rates of ≥ 90% of all colonoscopies in routine clinical practice
and ≥ 95% in screening colonoscopies are recommended. Unfortunately, the cecal intubation
rate in daily clinical practice is often lower than the target of ≥ 90%, with reported
percentages varying from 76.9% to 98.4%. This means that after an incomplete colonoscopy,
malignant and pre-malignant lesions may be missed if further investigation is not pursued.
Several explanatory factors for incomplete colonoscopy have been described. After an
incomplete conventional colonoscopy, patients are required to undergo another test to
complete the visualization of the colon. Options for incomplete examinations because of
anatomic reasons include both radiologic and endoscopic means.
CT Colonography (CTC ) permits to visualise the whole colon, is minimally invasive, does not
require sedation and is well accepted by the patient.
The PillCam Colon Capsule Endoscopy (Given® Diagnostic System)offers an alternative approach
for endoscopic visualization of the colon in patients with an incomplete conventional
colonoscopy. Advantages of the PillCam Colon Capsule Endoscopy (PCCE) include the
elimination of the need for sedation, the minimally invasive, painless nature of the exam,
no need of X-rays and the ability to pursue normal daily activities immediately following
the procedure. This is a study that is designed to evaluate the performance of the PCCE in
the evaluation of patients with an incomplete colonoscopy, compared to the CT-colonography.
PCCE and CT-colonography procedures will be compared in regards to completeness of the
procedure and detection of lesions in the colon that would have been missed by the
incomplete conventional colonoscopy.
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the
Western world, with 500000 deaths per year worldwide. Colonoscopy is accepted as a primary
CRC screening tool in many countries. As a preventative procedure, its main purpose is to
enable the early diagnosis of CRC at a curable stage and to identify and remove
pre-malignant adenomas. Cecal intubation is associated with an increased detection rate of
advanced neoplasia, as 33-50% of advanced neoplasia is located in the proximal colon.
Complete colonic evaluation is therefore a well-recognized measure of colonoscopy quality
control. Cecal intubation rates of ≥ 90% of all colonoscopies in routine clinical practice
and ≥ 95% in screening colonoscopies are recommended. Unfortunately, the cecal intubation
rate in daily clinical practice is often lower than the target of ≥ 90%, with reported
percentages varying from 76.9% to 98.4%. This means that after an incomplete colonoscopy,
malignant and pre-malignant lesions may be missed if further investigation is not pursued.
Several explanatory factors for incomplete colonoscopy have been described. Patient factors
that have been shown to increase the risk of an incomplete examination include advanced age,
female sex, previous abdominal/pelvic surgery, and diverticular disease. After an incomplete
conventional colonoscopy, patients are required to undergo another test to complete the
visualization of the colon. Options for incomplete examinations because of anatomic reasons
include both radiologic and endoscopic means.
CT Colonography (CTC ) permits to visualise the whole colon, is minimally invasive, does not
require sedation and is well accepted by the patient.
The present role of CTC is the integration as a replacement for barium enema in the case of
incomplete colonoscopy. In fact ,since 2006 the American Gastroenterological Association
(AGA) Clinical Practice and Economics Committee has endorsed CTC as the method of choice for
colon investigation in cases of incomplete colonoscopy and numerous evidence exists in the
literature showing a clear superiority of CTC over Barium Enema in the detection of CRC and
polyps.
Two large, multicenter trials [the American College of Radiology Imaging Network (ACRIN)
trial performed in the USA and Italian Multicenter Polyps Accuracy CTC study (IMPACT)trial
testing the performance of CTC in comparison with conventional colonoscopy reported that a
negative predictive values in both trials for CTC approaching 100%; this is extremely
important in order to reassure negative patients about the significance of the
examination.The PillCam Colon Capsule Endoscopy (Given® Diagnostic System)offers an
alternative approach for endoscopic visualization of the colon in patients with an
incomplete conventional colonoscopy. Advantages of the PillCam Colon Capsule Endoscopy
(PCCE) include the elimination of the need for sedation, the minimally invasive, painless
nature of the exam, no need of X-rays and the ability to pursue normal daily activities
immediately following the procedure. Furthermore, PCCE may be well accepted by the subjects,
thereby improving subjects' willingness to undergo a second diagnostic evaluation of the
colon after the failure of the first endoscopic examination and comply with colorectal
cancer screening recommendations. This is a study that is designed to evaluate the
performance of the PCCE in the evaluation of patients with an incomplete colonoscopy,
compared to the CT-colonography. PCCE and CT-colonography procedures will be compared in
regards to completeness of the procedure and detection of lesions in the colon that would
have been missed by the incomplete conventional colonoscopy.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |